Cannabis Europa 2025
The Barbican Centre, London, UK
European cannabis is the next frontier in legalisation and investment. Identify the next wave of opportunities and delve into crucial industry insights at Cannabis Europa London 2025.
Across Europe, governments are reevaluating their cannabis policies, leading to a patchwork of differing regulatory approaches. Countries like Germany, Italy, and the Netherlands have made significant steps towards legalizing medical cannabis, while others like Malta, Luxembourg, and Switzerland have moved to decriminalize or legalize adult recreational use. This shifting landscape is creating new market opportunities that will be covered in depth at Cannabis Europa London 2025.
We will bring together the brightest minds, most influential leaders, and innovative companies shaping the future of the European cannabis industry. By connecting policymakers, regulators, investors, entrepreneurs, and industry experts, our flagship European conference and expo will drive critical discussions and facilitate valuable partnerships to unlock the continent's vast potential.
W hy attend Cannabis Europa London 2025?
2-days of talks, networking and debates
Hear from globally renowned business leaders, academics and politicians
Hand picked exhibitors - a showcase of the best of the European cannabis industry
Networking sessions and Q&A’s with cannabis pioneers
Up to the minute market and policy insights
Exclusive VIP networking drinks reception in the beautiful conservatory space
Key Speakers
- Public health professionals and policymakers
- Barbara Burri who is a head of strategy at Zurich’s Municipal Health Services
- Business leaders
- FTI Consulting’s senior director, Ariadna Peretz
- Leading academics
- Professor of psychiatric research Sir Robin Murray from KCL
- Doctors and politicians
- Dr Sarah Wollaston - Doctor and former MP in the UK
Key Panels and Discussions
- The state of the cannabis industry in key markets such as Switzerland, Germany and France
- The history and future prospects of cannabis regulation, driving change and reform
Funding for the medical cannabis industry - Upcoming clinical trials and discussions on new cannabis derivatives such as CBN and delta-9
- Lessons learnt from different models in the USA
Some of our sponsors...
PHCANN International - a multinational pharmaceutical company, operating in accordance with EU GMP standards, with Headquarters in Amsterdam, Netherlands
Curaleaf - A publicly traded company (TSX: CURA) operating in North, the UK and EU
Linnea - Operating since 1982, Linnea has pursued the development of high quality botanical APIs in their sustainable GMP certified facility in Ticino, Switzerland
Aurora - (TSX: ACB) (NASDAQ: ACB) is a force in the rapidly expanding and evolving global cannabis market. With deep roots in Canada and a global outlook.
High Tide - Elevating the cannabis industry in Canada and abroad
